Specific variants in ftsI reduce carbapenem susceptibility in Pseudomonas aeruginosa

Hirokazu Yano1, Noboru Nakata2, Koji Yahara1

  • 1Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Higashimurayama, Tokyo, Japan.

PubMed

Insights

Seven specific mutations in the FtsI penicillin-binding protein (PBP3) gene reduce susceptibility to carbapenems in Pseudomonas aeruginosa. These FtsI variants also increase susceptibility to piperacillin and cefiderocol, offering insights into carbapenem resistance.

Area of Science:

  • Microbiology
  • Genetics
  • Pharmacology

Background:

  • The ftsI gene encodes penicillin-binding protein 3 (PBP3), a key target for beta-lactam antibiotics in gram-negative bacteria.
  • Genomic surveillance identified frequent nonsynonymous substitutions in ftsI among carbapenem-resistant Pseudomonas aeruginosa strains.
  • The independent contribution of ftsI substitutions to antimicrobial susceptibility in P. aeruginosa remains under-investigated.

Purpose of the Study:

  • To experimentally evaluate the impact of isolated ftsI nonsynonymous substitutions on the susceptibility of P. aeruginosa to various beta-lactam antibiotics.
  • To identify specific ftsI variants associated with carbapenem resistance and altered susceptibility profiles.
  • To provide a foundation for interpreting genomic data related to P. aeruginosa antimicrobial resistance.

Main Methods:

  • Introduction of specific ftsI nonsynonymous substitutions into an antimicrobial-susceptible P. aeruginosa strain via homologous recombination.
  • Assessment of beta-lactam susceptibility using broth microdilution and growth curve analysis.
  • Analysis of cocrystal structures of PBP3 with beta-lactams to understand mutation-induced structural changes.

Main Results:

  • A single N-terminal mutation (Leu89Val) did not affect beta-lactam susceptibility.
  • Seven penicillin-binding (PB) domain mutations (Met460Thr, Val471Gly, Arg504Cys, Pro527Thr, Pro527Ser, Phe533Leu, Val537Leu) conferred a two- to eightfold reduction in susceptibility to meropenem and doripenem.
  • The Arg504Cys mutation, common in clinical isolates, reduced cefepime susceptibility by fourfold.
  • These PB domain mutations increased susceptibility to cefiderocol and piperacillin.
  • Structural analysis suggested that PB domain mutations influence the mobility of key residues within PBP3.

Conclusions:

  • Seven specific ftsI variants act as genetic indicators of bacterial adaptation to carbapenems.
  • These findings elucidate the role of individual ftsI mutations in P. aeruginosa beta-lactam resistance.
  • The study facilitates the development of therapeutic strategies against carbapenem-resistant P. aeruginosa infections and aids genomic data interpretation.